Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). Symptomatic therapies to treat dry eyes, dry mouth, and/or specific extraglandular manifestations (commonly arthralgia and fatigue) are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Therapies with disease-modifying potential (e.g., Novartis’s iscalimab and ianalumab) are in development for SS, targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although such success has been a challenge to date.
QUESTIONS ANSWERED
How large is the SS population, and how will its size change over time?
How is SS currently managed? What are the usual treatments, and what drives their use?
Which unfulfilled clinical needs are the most pressing?
Which pipeline products are the most promising, and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
What are the drivers of and constraints in the SS market, and how will the market evolve through 2030?
CONTENT HIGHLIGHTS
Geographies: United States and EU5.
Primary research: Six country-specific interviews with thought-leading SS specialists supported by survey data collected for this study.
Epidemiology: Diagnosed and drug-treated prevalent cases of SS by country, diagnosed prevalence of primary and secondary SS.
Forecast: Drug-level sales and patient share of key SS therapies in 2020 and 2030.
Emerging therapies: Phase II: 7 key drugs; coverage of select early development products.